ArticleVirology journal2026
Coreceptor usage of plasma and cerebrospinal fluid-derived HIV-1 subtype C variants.
Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHIV-1 subtype C (HIV-1C) may use multiple coreceptors to enter cells. However, the differences in coreceptor usage between HIV-1C Env variants from peripheral blood and those from the central nervous system (CNS) are still not completely understood. This study characterised the coreceptor usage of viral populations that circulate in the central nervous system (CNS) and plasma compartments to enhance understanding of HIV-1C pathogenesis and inform the appropriate use of entry inhibitors.
methodsWe characterised the in vitro coreceptor usage of HIV-1C envelope protein (Env) variants circulating in peripheral blood and the cerebrospinal fluid (CSF) of twelve participants living with HIV and cryptococcal meningitis coinfection. We evaluated the coreceptor usage using Geno2pheno, Phenoseq and Web-PSSM coreceptor prediction tools, and confirmed coreceptor usage in U87 cell lines. We also analysed HIV-1 Env V3 loop characteristics for associations with CCR5 or CXCR4 usage.
resultsOur findings indicated that CSF-derived clones primarily used CCR5, while plasma-derived clones varied usage between CCR5, CXCR4 and CCR3 in vitro. HIV-1 Envs with a long V3 loop (37 amino acids), absence of potential N-linked glycosylation sites (PNGS), and a high net charge (> 5 +) were associated with CXCR4 usage. Whereas shorter or standard-length V3 loops (34-35 amino acids), presence of PNGS, lower net charge (range + 2 to + 5) and a GPGQ crown motif were associated with CCR5 usage.
conclusionOur findings reveal compartment-specific heterogeneity in HIV-1 subtype C coreceptor usage during advanced infection. CSF-derived variants were primarily limited to CCR5 usage, while plasma-derived variants exhibited broader usage of CXCR4 and alternative coreceptors. Phenotypic validation, together with distinct V3 loop signatures, provides evidence of viral adaptation to divergent tissue environments and highlights limitations of genotypic tropism prediction alone. These findings advance the understanding of HIV-1C pathogenesis and have implications for evaluating coreceptor usage in the context of entry inhibitor-based interventions particularly in regions where HIV-1C is endemic and diagnostic resources are limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.